Exchange: NASDAQ·Updated 09:57 AM EST

CV News

News
all
press releases
10x Genomics (TXG) Reports Q3 Loss, Beats Revenue Estimates
10x Genomics (TXG) delivered earnings and revenue surprises of +48.28% and +2.35%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
10x Genomics (TXG) Reports Q3 Loss, Beats Revenue Estimates
10x Genomics (TXG) delivered earnings and revenue surprises of +48.28% and +2.35%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
More News
CapsoVision (NASDAQ:CV) Trading Down 5.7% - Here's What Happened...
MarketBeat
CapsoVision, Inc. (NASDAQ:CV - Get Free Report) was the target of a significant increase in short interest during the month of March. As of March 31st, there was short interest totaling 1,244,098 shares, an increase of 124.8% from the March 15th total of 553,348 shares. Approximately 2.5% of the...
MarketBeat
CapsoVision, Inc. (NASDAQ:CV - Get Free Report) was the recipient of a large increase in short interest in the month of March. As of March 13th, there was short interest totaling 553,348 shares, an...
MarketBeat
Benchmark lowered their target price on shares of CapsoVision from $14.00 to $10.00 and set a "speculative buy" rating on the stock in a research note on Friday...
MarketBeat
CapsoVision (NASDAQ:CV) executives highlighted continued commercial growth for its CapsoCam Plus small-bowel capsule endoscopy product and provided updates on regulatory and clinical milestones for...
MarketBeat
(RTTNews) - CapsoVision, Inc (CV) will host a conference call at 4:30 PM ET on March 26, 2026, to discuss Q4 25 earnings results...
Nasdaq News: Markets
CapsoVision (NASDAQ:CV) executives used a fireside chat hosted by Roth Senior Research Analyst Kyle Bauser to outline the company's origins, its capsule endoscopy platform for small bowel visualization, and development plans for future GI indications including colon and pancreas. Management also dis...
MarketBeat
CapsoVision, Inc. (NASDAQ:CV - Get Free Report) was the recipient of a significant growth in short interest in the month of February. As of February 13th, there was short interest totaling 429,030...
MarketBeat
CapsoVision, Inc. (NASDAQ:CV - Get Free Report) saw a significant growth in short interest in January. As of January 30th, there was short interest totaling 357,735 shares, a growth of 281.0% from...
MarketBeat

Advertisement|Remove ads.